This symposium is part of the American Society of Hematology (ASH) 2026 meeting.
We invite you to meet with some of the experts in transplant and cellular therapy who are helping Roswell Park become a leading cellular therapy innovation engine!
Multiple myeloma care has entered a period of rapid change driven by immune-based therapies, particularly CAR T-cell therapies and T-cell engagers.
These approaches have created new opportunities for deep and durable responses in relapsed/refractory disease, but they have also introduced difficult clinical, operational, and translational questions that many providers must now address in routine practice.
Existing practice gaps that this symposium will aim to close include:
- Treatment selection and sequencing
- Understanding of clinical management after BCMA-directed therapy
- Toxicity recognition and longitudinal management
- Understanding of treatment resistance and mechanisms that influence immune therapy response
- Access to immune-based treatment and clinical implementation
Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care
American Society of Hematology Annual Meeting
Friday, December 11, 2026
3-6 p.m.
Registration will open soon.
Learning objectives
- Recommend optimized treatment and target selection of immune-based therapies for patients with multiple myeloma.
- Evaluate strategies for effective treatment of relapsed or refractory disease after treatment with immune-based therapies.
- Apply strategies to improve longitudinal care and collaboration between academic institutions and community-based physicians.
- Analyze tumor microenvironment for recommendation of treatment strategies.
- Diagnose and recommend appropriate toxicity management strategies for patients treated with immune-based therapies
Target audience
Hematologists, medical oncologists, cellular therapy physicians, transplant physicians, advanced practice providers, pharmacists, nurses, fellows, and other clinicians who care for patients with multiple myeloma, either in an academic or community-based setting
Register today!
Agenda
Time | Topic |
|---|---|
3-3:05 p.m. | Opening Remarks |
3:05-3:25 p.m. | CAR-T Cell Therapy for Myeloma |
3:25-3:45 p.m. | T Cell Engagers in Myeloma: When to Use Them |
3:45-4:05 p.m. | Toxicity Management for Immune-Based Therapies in Myeloma |
4:05-4:25 p.m. | Single-Cell Profiling of Myeloma Patients Treated with Immune Therapies |
4:25-4:40 p.m. | Break |
4:40- 5 p.m. | The Tumor Microenvironment of Myeloma: Impact on Chemotherapy and CAR T-Cell Therapy |
5:00 - 5:20 p.m. | Relapsed/Refractory Myeloma After BCMA-Directed Therapy: What Next? |
5:20- 5:40 p.m. | Academic-Community Partnerships for Myeloma Patients Receiving CAR T-Cell Therapy: |
5:40- 6 p.m. | Closing Remarks |
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Roswell Park Comprehensive Cancer Center. Roswell Park is accredited by the ACCME to provide continuing medical education for physicians.
Certification
Roswell Park designates this live activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial support was received from Legend Biotech, Kite Pharma, Inc, Johnson & Johnson, and Bristol Myers Squibb for this ASH satellite symposium.
ASH goals of the symposium
The symposium will provide a focused, expert-led educational program on the rapidly evolving use of immune-based therapies in multiple myeloma, with emphasis on CAR T-cell therapy, T-cell engagers, toxicity management, translational mechanisms of resistance, treatment after BCMA-directed therapy, and academic-community care models. The program is designed to help hematologists, oncologists, advanced practice providers, pharmacists, nurses, trainees, and translational investigators translate emerging clinical and biologic data into practical treatment decisions.
Specific goals are to improve participants’ ability to select and sequence immune therapies, manage acute and delayed toxicities, recognize mechanisms of resistance, identify options for patients progressing after BCMA-directed therapy, and strengthen referral and co-management pathways between community practices and specialized cellular therapy centers. Expected outcomes include increased clinician knowledge, greater confidence applying new data to patient care, and identification of practice changes that improve access, safety, and longitudinal outcomes for patients with myeloma.
Alignment with the ASH research agenda
This session is directly aligned with multiple pillars of the ASH Agenda for Hematology Research, including:
- Cellular Immunotherapies: Exploring how CAR T cells can be better utilized and improved in clinical settings.
- Drug Resistance: Investigating mechanisms of CAR T failure and strategies for overcoming relapse.
- Health Equity: Addressing geographic and systemic barriers to access with decentralized cell therapy models.
- Precision Medicine: Personalizing treatment sequencing for disease state and prior therapy.
- Health Services Research: Highlighting real-world treatment integration and healthcare delivery challenges in cellular therapy.
Each talk is designed to speak to these research priorities, providing attendees with forward-looking, clinically actionable content.
Financial relationships of planners & presenters
The following planners and presenters have either indicated financial relationships with ineligible companies (any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) or that no financial relationships exist. Policies and guidelines for identifying and mitigating relevant financial relationships of planners and presenters involved in accredited continuing education are in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.
All of the relevant financial relationships listed have been mitigated:
Renier Brentjens, MD, PhD, Consultant: Bristol Myers Squibb; Gracell Biotechnologies; Atara Biotherapeutics; CoImmune; Triumvira; Cargo Therapeutics, Legend Biotech Research funding: Bristol Myers Squibb Royalties or patent beneficiary: Bristol Myers Squibb; Caribou Biosciences Scientific Advisory Board member: CoImmune; Triumvira; Cargo Therapeutics. Marco Davila, MD, PhD, Consultant: Bristol Myers Squibb; A2 Biotherapeutics; Adaptive Biotechnology; Caribou Biosciences; CRISPR; Legend Biotech; Sythekine; Kite.